| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Lup-20(29)-en-28-oic acid, 3-oxo- does not have a single defined molecular target. As a pentacyclic lupane-type triterpenoid, it exhibits diverse biological activities including anti-tumor, anti-inflammatory, anti-parasitic, and anti-viral effects. The compound's activities are likely mediated through multiple mechanisms, including modulation of inflammatory pathways and direct effects on pathogens.
|
|---|---|
| ln Vitro |
Betulonic acid (72 hours) has IC50s of 17.7, 13.9, 25.7, 28.9, and 18.2 that inhibit the growth of many kinds of human tumor cell lines, such as MGC-803, PC3, Bcap-37, A375, and MCF-7. \M[2]. An IC50 of 10 μM is associated with betulonic acid's anti-plasmodium activity[3]. With EC50 values of 0.9, 73.32, and 5.7 µM, respectively, betulonic acid has the ability to suppress the HSV-1, ECHO6, and influenza FPV viruses[4].
In vitro, lup-20(29)-en-28-oic acid, 3-oxo- (betulonic acid) exhibits anti-tumor, anti-inflammatory, anti-parasitic, and anti-viral (HSV-1) activities. It is a bioactive compound found in many plants. Detailed in vitro activity data is limited in publicly available sources. |
| ln Vivo |
In vivo activity data for lup-20(29)-en-28-oic acid, 3-oxo- is limited. As a natural triterpenoid, it would be expected to have anti-tumor, anti-inflammatory, anti-parasitic, and anti-viral effects in vivo. Specific efficacy data and dosing regimens are not detailed in publicly available sources.
|
| Enzyme Assay |
Non-cellular assays for lup-20(29)-en-28-oic acid, 3-oxo- are not typically performed as it is not an enzyme inhibitor. The compound's identity and purity are confirmed by standard analytical methods such as NMR and mass spectrometry.
|
| Cell Assay |
In vitro cellular experiments involve treating cells with lup-20(29)-en-28-oic acid, 3-oxo- to assess its anti-tumor or anti-inflammatory effects. Cell viability, inflammatory cytokine production, and viral replication are measured. Specific protocols are described in the primary literature.
|
| Animal Protocol |
In vivo animal studies for lup-20(29)-en-28-oic acid, 3-oxo- would involve models of cancer, inflammation, parasitic infection, or viral infection. The compound would be administered via appropriate routes. Efficacy would be assessed by measuring tumor growth, inflammatory markers, parasite burden, or viral load.
|
| ADME/Pharmacokinetics |
Lup-20(29)-en-28-oic acid, 3-oxo- (betulonic acid) has a molecular weight of 454.68 g/mol and a molecular formula of C₃₀H₄₆O₃. It has a melting point of 253°C. The compound is found in many plants.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for lup-20(29)-en-28-oic acid, 3-oxo- is limited. As a natural triterpenoid, it is expected to have low toxicity. The compound is for research purposes only and should be handled with appropriate safety precautions.
|
| References |
|
| Additional Infomation |
Betulinic acid is a triterpenoid compound with anticoronavirus activity. It has been reported to be found in Eucalyptus compressus, Betula platyphylla var. japonica, and other organisms with relevant data. See also: Jujube (partial).
Lup-20(29)-en-28-oic acid, 3-oxo- (betulonic acid, betunolic acid, liquidambaric acid) is a pentacyclic lupane-type triterpenoid with anti-tumor, anti-inflammatory, anti-parasitic, and anti-viral activities. It is found in many plants. This product is for research purposes only and is not for human therapeutic use. |
| Molecular Formula |
C30H46O3
|
|---|---|
| Molecular Weight |
454.6844
|
| Exact Mass |
454.344
|
| CAS # |
4481-62-3
|
| PubChem CID |
122844
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
548.1±33.0 °C at 760 mmHg
|
| Melting Point |
264 °C
|
| Flash Point |
299.4±21.9 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.527
|
| LogP |
8.36
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
33
|
| Complexity |
902
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CCC(=O)C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)C)C(=O)O
|
| InChi Key |
SLJTWDNVZKIDAU-SVAFSPIFSA-N
|
| InChi Code |
InChI=1S/C30H46O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-22,24H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,24+,27-,28+,29+,30-/m0/s1
|
| Chemical Name |
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-prop-1-en-2-yl-2,3,4,5,6,7,7a,10,11,11b,12,13,13a,13b-tetradecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~6.67 mg/mL (~14.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.67 mg/mL (1.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.67 mg/mL (1.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1993 mL | 10.9967 mL | 21.9935 mL | |
| 5 mM | 0.4399 mL | 2.1993 mL | 4.3987 mL | |
| 10 mM | 0.2199 mL | 1.0997 mL | 2.1993 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
